AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11872412
Drug: Thin petrolatum
RxNorm normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin petrolatum (0.1 cc/25 cm2)
Trial: 11872412
Drug: Thick petrolatum
RxNorm normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thick petrolatum (0.3 cc/25 cm2)
Trial: 10458175
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 2.5 mg of dexamethasone disodium phosphate
Trial: 7581970
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of Pyridostigmine (PST)
Trial: 7581970
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of Pyridostigmine (PST)
Trial: 31119717
Drug: Behavioral physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral physical activity intervention (introductory personal training session followed by eight weekly 15-min PA behavioral coaching sessions)
Trial: 23927847
Drug: HP802‐247 (cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP802‐247 (cell therapy)
Trial: 16914379
Drug: Monthly nurse‐led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly nurse‐led lifestyle counselling (N=31)
Trial: 10971302
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg lamotrigine once daily for 6 days
Trial: 10971302
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g lithium gluconate anhydrous every 12 h for 5 days and in the morning of day 6
Trial: 3898481
Drug: 150 mOsm/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mOsm/L hypotonic solution
Trial: 18971533
Drug: Nattokinase (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nattokinase (2,000 FU/capsule) for 8 weeks
Trial: 18971533
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for 8 weeks
Trial: 17674310
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) only
Trial: 17674310
Drug: Oral poliovirus
RxNorm normalized name: poliovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral poliovirus vaccine (OPV) only
Trial: 9815533
Drug: Broccoli supplements,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli supplements, 3 g/day
Trial: 25680893
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg loading dose (LD)/90 mg bid maintenance dose (MD)
Trial: 18647232
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 120 mg day(-1) for 6 months
Trial: 17050867
Drug: irinotecan 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 60 mg/m2 and docetaxel 35 mg/m2 with celecoxib 400 mg twice daily
Trial: 17050867
Drug: irinotecan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 100 mg/m2 and gemcitabine 1,000 mg/m2 with celecoxib 400 mg twice daily
Trial: 1448711
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b (10 million U by subcutaneous injection, 3 times a week for 16 weeks)
Trial: 4052301
Drug: Diazepam 0.2
RxNorm normalized name: diazepam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.2 mg kg‐1
Trial: 4052301
Drug: Saline 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.04 ml kg‐1
Trial: 31662153
Drug: Stem cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cell therapy (various types including neural, haematopoietic, mesenchymal, differentiated embryonic stem cells, and induced pluripotent stem cells)
Trial: 25011604
Drug: Antibiotic mixing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic mixing (9 months) using third- or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems during consecutive antibiotic courses.
Trial: 25011604
Drug: Antibiotic cycling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic cycling (9 months) using third- or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems during consecutive 6-week periods.
Trial: 8271805
Drug: Treatment (recovery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (recovery method)
Trial: 31175909
Drug: brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brodalumab 210 mg every 2 weeks after ustekinumab
Trial: 29050498
Drug: Program B
RxNorm normalized name: ZINC OXIDE 3 g in 100 g / OCTOCRYLENE 6 g in 100 g / ENSULIZOLE 4 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g TOPICAL CREAM [NECK DECOLLETE HAND ARM DAY REPARATIVE HYDRATION RESCUE AND REPROGRAM BROAD SPECTRUM SPF 35 SUNSCREEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program B (acute medication restricted to two days/week)
Trial: 29050498
Drug: Program A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program A (no analgesics or acute migraine-medication)
Trial: 23967632
Drug: Acupuncture +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture + medication group
Trial: 24796042
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (triple-strong stimulation, acupuncture, acupuncture + medication)
Trial: 23081745
Drug: Fluticasone/formoterol (100/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol (100/10 or 250/10 μg b.i.d.)
Trial: 23081745
Drug: Fluticasone/salmeterol (100/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/salmeterol (100/50 or 250/50 μg b.i.d.)
Trial: 19752761
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy and atorvastatin (80 mg/day)
Trial: 19752761
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (atorvastatin)
Trial: 10188889
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg beta-carotene
Trial: 18160753
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg vitamin C
Trial: 18190651
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L PEG + E
Trial: 9422898
Drug: Dextromethorphan 60
RxNorm normalized name: DEXTROMETHORPHAN 60MG/GG 1200MG SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 60 mg
Trial: 9422898
Drug: Dextromethorphan 120
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 120 mg
Trial: 3830804
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for 3 years
Trial: 3830804
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone for 3 years (27 stage IIID and 36 stage IV patients)
Trial: 29866212
Drug: Intervention: Antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Antipsychotic treatment (specifics not provided)
Trial: 27609785
Drug: 20 G
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 G vitrectomy plus encircling band (group E1)
Trial: 27609785
Drug: 20 G
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 G vitrectomy without any buckle (group C)
Trial: 20170514
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of PEG‐IFN‐alpha-2a (180 ug/week) and ribavirin (800‐1200 mg/day)
Trial: 20170514
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of PEG‐IFN‐alpha-2a (180 ug/week) and ribavirin (800‐1200 mg/day)
Trial: 15884127
Drug: Control (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (200 mL of 5% dextrose water)
Trial: 12882432
Drug: Prompting intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompting intervention (weekly telephone or mail-delivered cues)
Trial: 30462939
Drug: Probiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactobacillus rhamnosus R0011 and L. helveticus R0052) at a dose of 4.0×10^9 CFUs twice daily for 5 days
Trial: 12632137
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.5% bupivacaine and 5 mg/ml epinephrine
Trial: 23867242
Drug: Qigong intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qigong intervention (1 hour, twice per week for 4 weeks)
Trial: 19302903
Drug: Multiple-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose oral SAMe (1000 mg)
Trial: 19302903
Drug: Multiple-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose IV SAMe (1000 mg)
Trial: 17825690
Drug: Salmeterol xinafoate/fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol xinafoate/fluticasone propionate (SFC) hydrofluoroalkane metered-dose inhaler (MDI) at 25/50 microg/actuation (group 1), 25/125 microg/actuation (group 2), or 25/250 microg/actuation (group 3), administered as 2 inhalations BID for 52 weeks.
Trial: 11725825
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg cisapride orally three times daily for 7 days
Trial: 9922587
Drug: TNK-t-PA (30-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNK-t-PA (30-40 mg in 15 s)
Trial: 9121623
Drug: Cigarettes with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes with 0.08 mg nicotine yield
Trial: 9121623
Drug: Cigarettes with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes with 0.17 mg nicotine yield
Trial: 9121623
Drug: Cigarettes with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes with 0.37 mg nicotine yield
Trial: 9121623
Drug: Cigarettes with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes with 0.48 mg nicotine yield
Trial: 9121623
Drug: Cigarettes with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes with 0.74 mg nicotine yield
Trial: 113129
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with all grafts patent
Trial: 113129
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with all grafts closed
Trial: 17414607
Drug: Preoperative hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative hepatic and regional arterial chemotherapy (PHRAC)
Trial: 21624304
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human brain natriuretic peptide (rhBNP)
Trial: 19139364
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) with 0.625 mg conjugated equine estrogens (CEE) with or without 2.5 mg medroxyprogesterone acetate (MPA)
Trial: 11258044
Drug: Flaxin tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxin tablets 5 mg (test formulation)
Trial: 2990350
Drug: MCNU and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCNU and radiation therapy
Trial: 30704266
Drug: Intranasal cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cellulose powder (ICP) 250 µg thrice daily (group B)
Trial: 30704266
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo 250 µg thrice daily (group C)
Trial: 25046279
Drug: SFC (250/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC (250/50 μg twice daily) combined with TIO (18 μg once daily)
Trial: 25046279
Drug: TIO alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIO alone (18 μg once daily)
Trial: 22799589
Drug: Boceprevir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boceprevir 800 mg single dose (Day 1 and Day 4)
Trial: 10464846
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol (50 micrograms b.i.d.)
Trial: 2301751
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg) plus diazepam (0.3 mg/kg) 1 h before induction (group 2)
Trial: 2301751
Drug: Pirenzepine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (50 mg) plus diazepam (0.3 mg/kg) on the evening before surgery and 1 h before induction (group 3)
Trial: 2301751
Drug: Diazepam (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.3 mg/kg) 1 h before induction (group 1)
Trial: 2301751
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg) plus diazepam (0.3 mg/kg) (group 2)
Trial: 2301751
Drug: Pirenzepine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (50 mg) plus diazepam (0.3 mg/kg) (group 3)
Trial: 6989685
Drug: Oxamethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxamethacin (100 mg t.i.d.)
Trial: 10215647
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg t.i.d.)
Trial: 26284338
Drug: Taxane treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane treatment (EC/T arm)
Trial: 26284338
Drug: CEF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF treatment (CEF arm)
Trial: 11578885
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg propofol (Group P)
Trial: 2437967
Drug: Progesterone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (25 mg vaginal suppositories twice daily)
Trial: 11911755
Drug: Intravenous nesiritide
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nesiritide
Trial: 12777951
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone (100 mg/daily)
Trial: 8558222
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant therapy with high-dose chemotherapy and autologous bone marrow support (ABMT)
Trial: 6134604
Drug: Propranolol 5
RxNorm normalized name: propranolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 5 mg intravenously
Trial: 31116675
Drug: anti-PD-1/L1 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1/L1 antibody
Trial: 26116581
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs and Aspirin
Trial: 18161260
Drug: Prophylactic clotting
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic clotting factor replacement therapy, cost USD 300,000 per patient per year, started after the first episode of joint bleeding early in life.
Trial: 18161260
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment started after the first episode of joint bleeding.
Trial: 15321800
Drug: trans-10,cis-12 CLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trans-10,cis-12 CLA (0.63, 1.26, and 2.52 g/d)
Trial: 15321800
Drug: cis-9,trans-11 CLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis-9,trans-11 CLA (0.59, 1.19, and 2.38 g/d)
Trial: 4904162
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of sustained release phenformin capsules administered twice daily
Trial: 26022965
Drug: Daily PROactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily PROactive instrument
Trial: 12404882
Drug: Amiloride (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (20 mg)
Trial: 21508131
Drug: Intranasal amiloride-sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal amiloride-sensitive potential
Trial: 7004742
Drug: Captopril 100
RxNorm normalized name: captopril 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 100 mg
Trial: 15223977
Drug: Magnesium chloride
RxNorm normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium chloride (MgCl2) 2.5 g daily
Trial: 10459960
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antihypertensive treatment)
Trial: 7994795
Drug: Oral 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-fluorouracil (5-FU) (Group B)
Trial: 7994795
Drug: Adriamycin and
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin and oral 5-FU (Group C)
Trial: 1094994
Drug: Chloramphenicol 0.5%
RxNorm normalized name: CHLORAMPHENICOL 0.5% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol 0.5% ophthalmic solution
Trial: 31619184
Drug: Medido medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medido medication dispenser
Trial: 15199083
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg/day for 9 days) with olanzapine (10 mg single dose on day 4)
Trial: 15199083
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg/day for 9 days) with clozapine (10 mg single dose on day 4)
Trial: 8236405
Drug: ivermectin treatment
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ivermectin treatment
Trial: 29769165
Drug: Potassium ferrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium ferrate haemostatic patch (PFHP)
Trial: 27524882
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (wPTX) 80 mg/m² intravenously on days 1, 8, and 15, every 4 weeks
Trial: 15668500
Drug: Antioxidant vitamin
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamin supplementation (500 mg vitamin C and 400 IU vitamin E daily)
Trial: 12456422
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg plus dexamethasone 8 mg after induction and placebo 12 h later (Group 3)
Trial: 12456422
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg plus droperidol 1.25 mg after induction and droperidol 1.25 mg 12 h later (Group 2)
Trial: 10334518
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (semustine, vincristine, and fluorouracil (5-FU) - MOF regimen)
Trial: 10334518
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (portal venous infusion of 5-FU)
Trial: 1743824
Drug: Vodka-tonic beverage
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vodka-tonic beverage containing a dose of vodka sufficient to induce a peak blood alcohol level of 0.05%
Trial: 8225624
Drug: Piperacillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (2 g)
Trial: 6459764
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G (4.8 X 10(6) U)
Trial: 25012577
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg clopidogrel MD with lansoprazole (30 mg/day)
Trial: 17578365
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogen 0.625 mg/day (n = 35)
Trial: 17578365
Drug: Intranasal 300
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 300 microg/day estradiol hemihydrate (n = 33)
Trial: 17578365
Drug: Percutaneous gel
RxNorm normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous gel 1.5 mg/day estradiol hemihydrate (n = 32)
Trial: 17578365
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group, n = 32)
Trial: 9563208
Drug: Sumatriptan 25
RxNorm normalized name: sumatriptan 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 25 mg
Trial: 1936480
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (short and intermediate‐acting insulin before breakfast and dinner)